Misha V. Blagosklonny graduated with an MD and PhD from First Pavlov State Medical
University of St. Petersburg, Russia. Dr. Misha V. Blagosklonny subsequently
Relocated to the USA, where he received the prestigious Fogarty Fellowship from the National Institutes of Health.
Within the period of his fellowship in Leonard Neckers’ laboratory at the National
Cancer Institute (NCI), he was a co-author of 18 publications on
Various biomedical topics, including targeting
HSP90, p53, Bcl2, Erb2, and Raf-1. He also was the last author for a clinical phase I/II
Trial article.
 
After authoring seven papers within the period of a brief yet resulting
Senior research fellowship in the El-Deiry Cancer Research Lab at the University of Pennsylvania,
Dr. Blagosklonny returned to NCI to work with Tito Fojo. Together, they
Published 26 papers. Moreover, Dr. Misha Blagosklonny published a
Lot of experimental research articles and theoretical papers as lead
Writer. The abovementioned sole-author articles
Encompassed two crucial themes.
The first of those mentioned selectively killing cancer
Cells with deregulated cell cycle or drug resistance by
Exploiting their resistance. The outcomes and underlying
Notion were so revolutionary that they were inadequately cited by
Other scientists as “reversal of resistance, ” even though the work was
Titled, “Exploiting of drug resistance instead of its reversal. ” One major
Supporter of this concept was the world-famous scientist Arthur Pardee, with whom Dr.
Blagosklonny co-authored a joint article in 2001.
 
The second theme throughout Dr. Blagosklonny’s sole-author articles
Is a research method to create knowledge via
Uniting several facts together from seemingly irrelevant areas.
This results in new notions with testable predictions, which in
Turn can be “tested” via analyzing the literature further. Likewise, the
Notion was co-authored by Arthur Pardee in a 2002 publication in Nature. The
First success of the new research methodology was the description of the feedback
Regulation of p53, as supported by the discovery of mdm2/p53 loop; and the
Explanation why mutant p53 is always overexpressed, published in 1997. The most
Crucial result revealed by Dr.
Blagosklonny’s research methodology is the hyperfunction (or quasi-programmed)
Theory of aging and the revelation of rapamycin as an exceptionally well-tolerated
Anti-aging medicine, published in 2006. As mentioned in Scientific American,
Michael Hall, who discovered mTOR in 1991, gives Dr. Blagosklonny credit for
“connecting dots that others cannot even see. ”
 
In 2002, Dr. Blagosklonny became associate professor of medicine at New York Medical College.
He went on to assume responsibilities as a senior scientist at Ordway
Research Institute in Albany, New York, in 2005, before receiving another
Position at Roswell Park Cancer Institute as professor of oncology in 2009.
 
Since coming to Roswell Park Comprehensive Cancer Center in 2009, Dr. Blagosklonny
Has studied the prevention of cancer (an age-related disease) by
Stopping body aging — in other words, “preventing cancer
Via remainng young. ” His laboratory closely collaborated with
Andrei Gudkov’s and finalized research on the suppression of
Cellular senescence, namely suppression of cellular conversion from healthy quiescence to
Permanent senescence. This resulted in the discovery of extra anti-aging
Drugs besides rapamycin. The cell culture studies were
Accompanied by studies in mice, including a few models such as
Normal and aging mice, p53-deficient mice, and mice on a high-fat diet.
 
Dr. Misha Blagosklonny has also published extensively on the stoppage of cellular
Senescence via rapamycin and other mTOR inhibitors, life
Prolongation and cancer prevention in mice, and combinations of anti-
Aging medicines to be appliedamong humans. A
Rapamycin-based combination of seven clinically available medicines has
Been named the “Koschei Formula” and is now used for the treatment of aging in patients
At the Alan Green Clinic in Little Neck, New York.